Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 12/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 10/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 7/20 | 0.43 |
| ▸ | CA9 | Q16790 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyanide SCHEMBL27784410 | 0.95 | ALDH1A1 (0.47) | ALDH1A1ADRA2BPTGS1TDP1CA2 | |
| SCHEMBL6807395 | 0.88 | CA2 (0.51) | ALDH1A1ADRA2BPTGS1TDP1CA2 | |
| SCHEMBL28499563 | 0.85 | ALDH1A1 (0.52) | ALDH1A1ADRA2BPTGS1TDP1CA2 | |
| SCHEMBL1607774 | 0.83 | ALDH1A1 (0.50) | ALDH1A1ADRA2BPTGS1TDP1CA2 | |
| SCHEMBL5763665 | 0.83 | ALDH1A1 (0.50) | ALDH1A1ADRA2BPTGS1TDP1CA2 | |
| SCHEMBL3600104 | 0.81 | CA2 (0.46) | ALDH1A1CA2CA1ACHECA12 | |
| SCHEMBL31536843 | 0.81 | CA2 (0.46) | ALDH1A1CA2CA1ACHECA12 | |
| SCHEMBL6731762 | 0.79 | CA2 (0.47) | ALDH1A1CA2CA1ACHECA12 | |
| SCHEMBL3772307 | 0.79 | CA2 (0.45) | ALDH1A1CA2CA1ACHECA12 | |
| SCHEMBL5399765 | 0.79 | PTGES2 (0.54) | ALDH1A1PTGS1TDP1CA2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| EP-2266977-B1 | 2,4-di[(hetero)arylamino]-pyrimidine derivatives as zap-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-20130345180-A1 | 2,4- DIAMINOPYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-12-26 | — | — | US | disclosed |
| EP-1487805-A1 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004052313-A2 | ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052312-A2 | ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040043987-A1 | Novel compounds and their use as positive AMPA receptor modulators | NEUROSEARCH A/S. | 2004-03-04 | — | — | US | disclosed |
| US-6635635-B2 | 5,5-dioxo-2,3,3a,4-tetrahydro-1 H-pyrrolo(2,1-c)(1,2,4)-benzothiadiazin-7-ol, for example; nervous system disorders; alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) modulators | LES LABORATOIRES SERVIER (FR) | 2003-10-21 | — | — | US | disclosed |
| WO-2003078404-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |
| US-20020037894-A1 | Benzothiadiazine compounds | ADIR ET COMPAGNIE (FR) | 2002-03-28 | — | — | US | disclosed |
| EP-1176148-A1 | Benzothiadiazine derivatives, processes for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2002-01-30 | — | — | EP | disclosed |
| EP-1071426-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999042456-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | ALDH1A1 4333/4885ADRA2B 1067/4885PTGS1 2100/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | ALDH1A1 3674/4885ADRA2B 1129/4885PTGS1 1994/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | ALDH1A1 4333/4885ADRA2B 1067/4885PTGS1 2100/4885 |
| US-20020037894-A1 | Benzothiadiazine compounds | HCAR1, GLRA1, HCAR2 | ALDH1A1 239/4885ADRA2B 155/4885PTGS1 1520/4885 |
| US-20040043987-A1 | Novel compounds and their use as positive AMPA receptor modulators | GRIK4, GRIA4, GRM2 | ALDH1A1 3816/4885ADRA2B 536/4885PTGS1 1087/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | ALDH1A1 4184/4885ADRA2B 1086/4885PTGS1 1996/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | ALDH1A1 4184/4885ADRA2B 1086/4885PTGS1 1996/4885 |
| US-20130345180-A1 | 2,4- DIAMINOPYRIMIDINE DERIVATIVES | ZAP70, SYK, BTK | ALDH1A1 3656/4885ADRA2B 3041/4885PTGS1 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.